Seeking Alpha

BioMimetic Therapeutics (BMTI) soars 16.1% after submitting more information to the FDA about...

BioMimetic Therapeutics (BMTI) soars 16.1% after submitting more information to the FDA about its Augment treatment, saying that the bone-graft product is not inferior to autograft. The agency decided not to OK Augment in January, when it asked for the additional data. BioMimetic now expects a decision on approval next year or in early 2014. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs